Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)

doi:10.1038/leu.2009.268

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)

The Hull York Medical School

Research output: Contribution to journal › Review article › peer-review

Abstract

Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.

Original language	English
Pages (from-to)	521-35
Number of pages	15
Journal	Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Volume	24
Issue number	3
DOIs	https://doi.org/10.1038/leu.2009.268
Publication status	Published - Mar 2010

Keywords

Flow Cytometry
Fusion Proteins, bcr-abl/genetics
Gene Rearrangement
Genes, Immunoglobulin
Humans
Neoplasm, Residual/diagnosis
Polymerase Chain Reaction
Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis

Access to Document

10.1038/leu.2009.268

Cite this

European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) (2010). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 24(3), 521-35. https://doi.org/10.1038/leu.2009.268

@article{5e7fc5b588c64e26866fee22f0365599,

title = "Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008",

abstract = "Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.",

keywords = "Flow Cytometry, Fusion Proteins, bcr-abl/genetics, Gene Rearrangement, Genes, Immunoglobulin, Humans, Neoplasm, Residual/diagnosis, Polymerase Chain Reaction, Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis",

author = "{European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)} and M Br{\"u}ggemann and A Schrauder and T Raff and H Pfeifer and M Dworzak and Ottmann, {O G} and V Asnafi and A Baruchel and R Bassan and Y Benoit and A Biondi and H Cav{\'e} and H Dombret and Fielding, {A K} and R Fo{\`a} and N G{\"o}kbuget and Goldstone, {A H} and N Goulden and G Henze and D Hoelzer and Janka-Schaub, {G E} and Macintyre, {E A} and R Pieters and A Rambaldi and J-M Ribera and K Schmiegelow and O Spinelli and J Stary and {von Stackelberg}, A and M Kneba and M Schrappe and {van Dongen}, {J J M}",

year = "2010",

month = mar,

doi = "10.1038/leu.2009.268",

language = "English",

volume = "24",

pages = "521--35",

journal = "Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K",

issn = "1476-5551",

number = "3",

}

European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) 2010, 'Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008', Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, vol. 24, no. 3, pp. 521-35. https://doi.org/10.1038/leu.2009.268

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. / European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL).
In: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 24, No. 3, 03.2010, p. 521-35.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Standardized MRD quantification in European ALL trials

T2 - proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

AU - European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)

AU - Brüggemann, M

AU - Schrauder, A

AU - Raff, T

AU - Pfeifer, H

AU - Dworzak, M

AU - Ottmann, O G

AU - Asnafi, V

AU - Baruchel, A

AU - Bassan, R

AU - Benoit, Y

AU - Biondi, A

AU - Cavé, H

AU - Dombret, H

AU - Fielding, A K

AU - Foà, R

AU - Gökbuget, N

AU - Goldstone, A H

AU - Goulden, N

AU - Henze, G

AU - Hoelzer, D

AU - Janka-Schaub, G E

AU - Macintyre, E A

AU - Pieters, R

AU - Rambaldi, A

AU - Ribera, J-M

AU - Schmiegelow, K

AU - Spinelli, O

AU - Stary, J

AU - von Stackelberg, A

AU - Kneba, M

AU - Schrappe, M

AU - van Dongen, J J M

PY - 2010/3

Y1 - 2010/3

N2 - Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.

AB - Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.

KW - Flow Cytometry

KW - Fusion Proteins, bcr-abl/genetics

KW - Gene Rearrangement

KW - Genes, Immunoglobulin

KW - Humans

KW - Neoplasm, Residual/diagnosis

KW - Polymerase Chain Reaction

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis

U2 - 10.1038/leu.2009.268

DO - 10.1038/leu.2009.268

M3 - Review article

C2 - 20033054

SN - 1476-5551

VL - 24

SP - 521

EP - 535

JO - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

JF - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

IS - 3

ER -

European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2010 Mar;24(3):521-35. doi: 10.1038/leu.2009.268